Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Antiretroviral neurotoxicity.

Robertson K, Liner J, Meeker RB.

J Neurovirol. 2012 Oct;18(5):388-99. doi: 10.1007/s13365-012-0120-3. Epub 2012 Jul 19.

2.

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D.

HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243. Epub 2015 Feb 27.

3.

Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.

Blas-García A, Polo M, Alegre F, Funes HA, Martínez E, Apostolova N, Esplugues JV.

J Antimicrob Chemother. 2014 Nov;69(11):2995-3000. doi: 10.1093/jac/dku262. Epub 2014 Jul 9.

PMID:
25011651
5.

Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.

Wright EJ.

Curr Opin HIV AIDS. 2009 Sep;4(5):447-52. doi: 10.1097/COH.0b013e32832dd0c2. Review.

PMID:
20048710
6.

HIV-1-associated central nervous system dysfunction.

Krebs FC, Ross H, McAllister J, Wigdahl B.

Adv Pharmacol. 2000;49:315-85. Review.

PMID:
11013768
7.

Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz.

Funes HA, Apostolova N, Alegre F, Blas-Garcia A, Alvarez A, Marti-Cabrera M, Esplugues JV.

J Infect Dis. 2014 Nov 1;210(9):1385-95. doi: 10.1093/infdis/jiu273. Epub 2014 May 9.

PMID:
24813473
8.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
9.

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA.

JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.

PMID:
18677028
10.

Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.

Di Yacovo MS, Moltó J, Ferrer E, Curran A, Else L, Gisslén M, Clotet B, Tiraboschi JM, Niubò J, Vila A, Zetterberg H, Back D, Podzamczer D.

J Antimicrob Chemother. 2015 May;70(5):1513-6. doi: 10.1093/jac/dku558. Epub 2015 Jan 20.

PMID:
25608583
11.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
12.

Neuroprotective and anti-human immunodeficiency virus activity of minocycline.

Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S.

JAMA. 2005 Apr 27;293(16):2003-11.

PMID:
15855434
13.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
14.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

15.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):410-25. doi: 10.1001/jama.2014.8722.

PMID:
25038359
16.

U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.

Mofenson LM; Centers for Disease Control and Prevention, U.S. Public Health Service Task Force.

MMWR Recomm Rep. 2002 Nov 22;51(RR-18):1-38; quiz CE1-4.

17.

[Antiretroviral therapy and mitochondrial toxicity].

Santos Corraliza E, Fuertes Martín A.

Med Clin (Barc). 2007 Mar 3;128(8):311-6. Review. Spanish.

PMID:
17338866
18.

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.

PMID:
19731418
19.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
20.

Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons.

Borgmann K, Rao KS, Labhasetwar V, Ghorpade A.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):853-62. doi: 10.1089/AID.2010.0295. Epub 2011 Feb 2.

Supplemental Content

Support Center